Correlation of autoantibodies and CD5+ B cells in ocular adnexal marginal zone B cell lymphomas
- 1Department of Ophthalmology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
- 2Department of Pathology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
- 3Department of Pathology, Okayama University Graduate School of Medical, Dentistry and Pharmaceutical Science, Okayama, Japan
- 4Department of Internal Medicine, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
- 5Department of Ophthalmology, Nagoya University Medical School, Nagoya, Japan
- Correspondence to Toshinobu Kubota, Department of Ophthalmology, National Hospital Organization, Nagoya Medical Center, 4-1-1, Sannomaru, Naka-ku, Nagoya-shi, Aichi-ken, 460-0001, Japan; ganiky{at}nnh.hosp.go.jp
- Accepted 11 September 2009
Abstract
Aim: To determine the clinicopathological properties of ocular adnexal marginal zone B cell lymphomas (MZBLs) with CD5+ B cells.
Methods: This study determined the clinicopathological properties of MZBL samples from 97 patients with ocular adnexal MZBLs and searched for hallmarks of systemic autoimmunity in these patients.
Results: Two elderly female patients were found to have ocular adnexal MZBLs with CD5+ B cells; flow cytometry analysis suggested that one of these MZBLs had CD5+ B cell clonal proliferation. The levels of anti-single stranded (SS)-DNA and anti-SS-A/Ro antibodies in these two patients were significantly higher than those in controls that were matched for age, gender and disease (2/2 versus 0/14; p = 0.008) and controls without MZBL (2/2 versus 0/30; p = 0.002). The genes from the immunoglobulin heavy-chain variable region for one of the patients showed a V3-21 segment. In addition, another patient with ocular adnexal reactive lymphoid hyperplasia with CD5+ B cells also had anti-SS-DNA antibodies.
Conclusion: Patients with ocular adnexal MZBLs with CD5+ B cells may have a background of systemic conditions with CD5+ B-cell-related autoantibodies.
Footnotes
-
Competing interests None.
-
Ethics approval Ethics approval was obtained from the Ethics Committee at Nagoya Medical Center, Nagoya, Japan.
-
Provenance and Peer review Not commissioned; externally peer reviewed.
